Deep vein thrombosis (DVT) affects 10 million individuals worldwide each year, with a global treatment market of up to $2.03 billion in 2034. Given that DVT treatments, thrombolytics, are given frequently and in high doses, we have engineered a novel solution to enhance DVT treatment. Starting with DVT we plan to expand to other cardiovascular diseases to target the global thrombosis market.
Parabolis has 2 co-founders: Yimo Yan and Josh Mesfin. Yimo has microfluidics and microsized materials experience. Josh has biomaterial design and cardiovascular translational research experience. Here, we have made a novel solution towards improving DVT treatments.
